基本信息
浏览量:88
职业迁徙
个人简介
At Biogen, he led discovery sciences, translational medicine, clinical development, and regulatory sciences, with a focus on neurological, immunological, and rare diseases.
He significantly expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza™️ (nusinersen), the first drug approved for spinal muscular atrophy.
At Pfizer, he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis, and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic.
He significantly expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza™️ (nusinersen), the first drug approved for spinal muscular atrophy.
At Pfizer, he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis, and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic.
研究兴趣
论文共 253 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn